|
Open-Label Study of ALIMTA (pemetrexed) and Cisplatin in chemonaive patients with malignant Pleural Mesothelioma.
ALIMTA (pemetrexed) is available as compassionate use to medically eligible patients with malignant mesothelioma. Patients who have been diagnosed with Malignant Pleural Mesothelioma and have not yet received any treatment may be eligible for ALIMTA. The FDA approved the compassionate use of this drug based on preliminary results from clinical trials. Findings show that patients treated with ALIMTA and Cisplatin survive longer and experience less pain and shortness of breath than those treated with Cisplatin alone.
Location/Contact Information:
Ivette Farmer, MD, MPH
Southwestern Regional Medical Center
2408 E. 81st Street, Suite 100
Tulsa, OK 74137
Telephone: 918-496-5933 or 1-800-788-8485
Fax: 918-496-5455
Email: ivette.farmer@ctcoftulsa.com
|
 |
|
